Oncology Update

Do specialised, next-generation drugs offer value for money?

PBS approval for an expensive new drug raises an important question.

Please Login to Access Medical Observer

If you have an account select Login. If you are new to Medical Observer select Join.

Login Join


Michael Woodhead

Michael Woodhead is clinical news editor across Australian Doctor Group’s publications.


Ensure you never miss a big story by signing up for our daily e-newsletter.